Autologous stem cell transplant for patients with diffuse systemic sclerosis (SSc), without selecting for a particular hematopoietic cell type, performed about as well in a new single-arm trial as ...

We compared myeloablative CD34+ selected autologous hematopoietic stem-cell transplantation with immunosuppression by means of 12 monthly infusions of cyclophosphamide in patients with scleroderma.

Contrary to autologous ‘rescue’ stem cell transplantation, the latter approaches avoid giving back cells with possible tumor contamination. We collected data on eight patients who received aut ...

Five other published randomized studies have compared conventional chemotherapy with autologous stem-cell transplantation. 19–23 Overall, transplantation improved the response rate (60 to 80% vs.

Hematopoietic stem cell transplantation ... from around $140,000 for an autologous HSCT to nearly $290,000 for an allogeneic HSCT with a myeloablative pre-transplant treatment.

Autologous stem cell transplantation, according to the National Cancer Institute ... That is reasonable and this study provides a pathway to do that. Transcript has been edited for clarity and ...

Autologous stem cell transplantation (ASCT) is a popular treatment option for eligible individuals with multiple myeloma. It can allow people with multiple myeloma to grow healthy blood cells again.

Compared to conventional chemotherapy, autologous stem cell transplantation can extend "event-free survival" for breast cancer patients. Clinical trials provide proof of this for breast cancer ...

Survival in newly diagnosed multiple myeloma improved significantly in patients who underwent early autologous stem cell transplantation (ASCT), according to pooled data from two randomized trials.

Autologous stem cell transplant plus Rituxan did not improve survival outcomes in certain patients with mantle cell lymphoma compared with Rituxan alone. Patients with mantle cell lymphoma (MCL) did ...

Source Reference: Jurkunas UV, et al "Cultivated autologous limbal epithelial cell (CALEC) transplantation for limbal stem cell deficiency: A phase I/II clinical trial of the first xenobiotic-free ...